Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiforme

Vascular endothelial growth factor receptors (VEGFRs) have emerged as the most promising anti-angiogenic therapeutic targets for the treatment of recurrent glioblastomas (GBM). However, anti-VEGF treatments led to the high proportion of non-responder patients or non lasting clinical response and the tumor progression to the greater malignant stage. To overcome these problems, there is an utmost need to develop innovative anti-angiogenic therapies. In this study, we report the development of a series of new FGFR1 inhibitors. Among them, compound 4i was able to potently inhibit FGFR1 kinase activities both in vitro and in vivo. This compound displayed strong anti-angiogenic activity in HUVECs and anti-tumor growth and anti-invasion effects in U-87MG cell line. These results emphasize the importance of FGFR1-mediated signaling pathways in GBM and reveal that pharmacological inhibition of FGFR1 can enhance the anti-tumoral, anti-angiogenic and anti-metastatic efficiency against GBM. These data support targeting of FGFR1 as a novel anti-angiogenic strategy and highlight the potential of compound 4i as a promising anti-angiogenic and anti-metastatic candidate for GBM therapy.

Automated summary

Vascular endothelial growth factor receptors (VEGFRs) have shown promise as therapeutic targets for recurrent glioblastomas (GBM). However, current anti-VEGF treatments have limitations, leading to non-responsiveness and tumor progression. This study focuses on the development of FGFR1 inhibitors that potently inhibit FGFR1 kinase activities, displaying anti-angiogenic, anti-tumor growth, and anti-invasion effects. These findings highlight the significance of FGFR1 signaling in GBM and suggest the potential of targeting FGFR1 as a novel anti-angiogenic strategy.